LivaNova PLC (LIVN) Stock Analysis

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

Fri, October 23, 2026 at 1:00 PM UTC 2 min read

LivaNova (LIVN) announced the publication of full 36-month results from its CORE-VNS study, highlighting sustained and increasing benefits of its VNS therapy for drug-resistant epilepsy. This positive data reinforces the efficacy of LivaNova's neuromodulation technology, potentially enhancing its market position and driving future sales growth. Investors may view this development as a significant indicator of the company's long-term viability and innovation in treating challenging medical conditions.

Read full article →

Operating Leverage and Product Innovation Drive LivaNova’s(LIVN) Sustained Profit Outlook

Thu, September 24, 2026 at 1:50 PM UTC 2 min read

LivaNova (LIVN) reported strong operating leverage and ongoing product innovation, which have contributed to a sustained profit outlook. This positive performance indicates the company's ability to efficiently manage costs while enhancing its product offerings, making it an attractive option for investors seeking growth potential. The sustained profit outlook suggests LivaNova is well-positioned to navigate market challenges and capitalize on future opportunities.

Read full article →